News

Pharmaceutical Technology on MSN1d
MetrioPharm gains orphan drug status from EMA for MP1032
The approval is supported by strong preclinical data demonstrating MP1032's capacity to sustain muscle function.
FDA Probes Death Of 8-Year-Old Who Received Sarepta's Elevidys
The U.S. Food and Drug Administration (FDA) announced on Friday, after market close, that it is investigating the death of an ...
DPA International on MSN5d
EMA recommends approval of additional Alzheimer's treatment
The European Medicines Agency (EMA) cleared the way for the use of another drug to treat Alzheimer's disease on Friday.
Business Wire20d
FDA and EMA Accept Regulatory Submission for Pfizer’s Ritlecitinib ...
Contacts Media Relations: +1 (212) 733-1226 [email protected] Investor Relations: +1 (212) 733-4848 [email protected] Industry: Biotechnology FDA Health Pharmaceutical Clinical Trials ...
Medscape1d
EMA Turns Down Nurzigma for Huntington Disease
The drug failed to meet its primary endpoints in clinical trials, but subgroup analyses hinted at modest benefits.
Nasdaq27d
FDA And EMA Approve AB Science's Phase 3 Masitinib Trial In MCRPC - Nasdaq
(RTTNews) - AB Science (ABSCF.PK) announced FDA and EMA authorization of a confirmatory Phase 3 trial of masitinib in metastatic castrate-resistant prostate cancer, using a harmonized protocol and ...
Business Wire2y
FDA and EMA Accept Regulatory Submission for Pfizer’s Ritlecitinib ...
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) accepted for filing the New Drug Application (NDA) for ritlecitinib ...
Nasdaq27d
FDA And EMA Approve AB Science's Phase 3 Masitinib Trial In MCRPC
(RTTNews) - AB Science (ABSCF.PK) announced FDA and EMA authorization of a confirmatory Phase 3 trial of masitinib in metastatic castrate-resistant prostate cancer, using a harmonized protocol and ...